Language selection

Search

Details for: XELJANZ XR

Company: PFIZER CANADA ULC

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02470608XELJANZ XRTOFACITINIB (TOFACITINIB CITRATE)11 MGTABLET (EXTENDED-RELEASE)ORAL
Search Reported Side Effects Report a Side Effect

Summary Reports

Summary Safety Review - Xeljanz and Xeljanz XR (tofacitinib) and Jakavi (ruxolitinib) - Janus Kinase (JAK) inhibitors - Assessing the Potential Risk of Blood Clots in the Deep Veins (Venous Thromboembolic Events)
Summary Safety Review - Xeljanz/Xeljanz XR (tofacitinib) - Assessing the Potential Risks of Serious Heart-related Problems and Cancer

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: